Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase III Multicenter Randomized Clinical Trial Comparing Gemcitabine Alone Or In Combination With Capecitabine For The Treatment Of Patients With Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if gemcitabine is more effective with or without capecitabine in treating pancreatic cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of gemcitabine with or without capecitabine in treating patients who have locally advanced or metastatic pancreatic cancer.
調査の概要
詳細な説明
OBJECTIVES:
- Compare the 1-year survival rate of patients with locally advanced or metastatic pancreatic cancer treated with gemcitabine with or without capecitabine.
- Compare the median and 2-year survival rates and the objective response rates of patients treated with these regimens.
- Compare the toxicity of these regimens in these patients.
- Compare the quality of life of patients treated with these regimens.
OUTLINE: This is an randomized, open-label, multicenter study. Patients are stratified according to disease stage (locally advanced vs metastatic) and performance status (0 and 1 vs 2). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 1-21. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive gemcitabine IV over 30 minutes on days 1, 8, 15, 22, 29, 36, and 43 during the first course. After a 1-week rest period, patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15. Subsequent courses repeat every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, every 3 months for 1 year, and then annually thereafter.
Patients are followed every 3 months.
Peer Reviewed and Funded or Endorsed by Cancer Research UK
PROJECTED ACCRUAL: A total of 508 patients (254 per treatment arm) will be accrued for this study.
研究の種類
入学 (予想される)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
England
-
Bath、England、イギリス、BA1 3NG
- Royal United Hospital
-
Bournemouth、England、イギリス、BH7 7DW
- Royal Bournemouth Hospital
-
Bristol、England、イギリス、BS2 8ED
- Bristol Haematology and Oncology Centre
-
Cambridge、England、イギリス、CB2 2QQ
- Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust
-
Derby、England、イギリス、DE1 2QY
- Derbyshire Royal Infirmary
-
Exeter、England、イギリス、EX2 5DW
- Royal Devon and Exeter Hospital
-
Ipswich、England、イギリス、IP4 5PD
- Ipswich Hospital NHS Trust
-
King's Lynn、England、イギリス、PE30 4ET
- Queen Elizabeth Hospital
-
Leeds、England、イギリス、LS16 6QB
- Cookridge Hospital at Leeds Teaching Hospital NHS Trust
-
Leicester、England、イギリス、LE1 5WW
- Leicester Royal Infirmary
-
Lincoln、England、イギリス、LN2 5QY
- Lincoln County Hospital
-
Liverpool、England、イギリス、L69 3GA
- Royal Liverpool University Hospital
-
Liverpool、England、イギリス、L3 9TA
- Cancer Research UK Liverpool Cancer Trials Unit
-
London、England、イギリス、SE1 7EH
- St. Thomas' Hospital
-
Manchester、England、イギリス、M20 4BX
- Christie Hospital NHS Trust
-
Merseyside、England、イギリス、CH63 4JY
- Clatterbridge Centre for Oncology NHS Trust
-
Middlesbrough, Cleveland、England、イギリス、TS4 3BW
- James Cook University Hospital at South Tees Hospitals NHS Trust
-
Newcastle-Upon-Tyne、England、イギリス、NE4 6BE
- Northern Centre for Cancer Treatment at Newcastle General Hospital
-
Norwich、England、イギリス、NR4 7UY
- Norfolk and Norwich University Hospital
-
Plymouth、England、イギリス、PL6 8DH
- Derriford Hospital
-
Poole Dorset、England、イギリス、BH15 2JB
- Poole Hospital NHS Trust
-
Prescot Merseyside、England、イギリス、L35 5DR
- Whiston Hospital
-
Preston、England、イギリス、PR2 9HT
- Royal Preston Hospital
-
Salisbury、England、イギリス、SP2 8BJ
- Salisbury District Hospital
-
Southampton、England、イギリス、SO14 0YG
- Royal South Hants Hospital
-
Stoke-On-Trent、England、イギリス、ST4 7LN
- University Hospital of North Staffordshire
-
Sutton、England、イギリス、SM2 5PT
- Royal Marsden NHS Foundation Trust - Surrey
-
Warrington、England、イギリス、WA5 1QG
- Warrington Hospital NHS Trust
-
-
Scotland
-
Aberdeen、Scotland、イギリス、AB25 2ZN
- Aberdeen Royal Infirmary
-
-
Wales
-
Swansea、Wales、イギリス、SA2 8QA
- Singleton Hospital of the Swansea NHS Trust
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed ductal adenocarcinoma of the pancreas
- Locally advanced or metastatic disease not amenable to curative surgical resection
- Macroscopic residual disease after prior resection with histological confirmation is allowed
- Unidimensionally measurable disease
- No intracerebral metastases or meningeal carcinomatosis
PATIENT CHARACTERISTICS:
Age:
- Over 18
Performance status:
- WHO 0-2
Life expectancy:
- More than 3 months
Hematopoietic:
- WBC greater than 3,000/mm3
- Neutrophil count greater than 1,500/mm3
- Platelet count greater than 100,000/mm3
Hepatic:
- Bilirubin less than 2 mg/dL
Renal:
- Creatinine less than 2 mg/dL
- Creatinine clearance greater than 50 mL/min
Cardiovascular:
- No New York Heart Association class III or IV heart disease
- No uncontrolled angina pectoris
Other:
- No other prior malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix
- No other concurrent uncontrolled medical condition
- No other medical or psychiatric condition that would preclude study
- No known hypersensitivity to fluorouracil
- No dihydropyrimidine dehydrogenase deficiency
- No known malabsorption syndromes
- Not pregnant or nursing
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- No prior chemotherapy (including preoperative or adjuvant) for this disease
- No other concurrent cytotoxic chemotherapy
Endocrine therapy:
- Not specified
Radiotherapy:
- No prior radiotherapy (including preoperative or adjuvant) for this disease
Surgery:
- See Disease Characteristics
Other:
- No prior investigational drugs (including preoperative or adjuvant) for this disease
- No other concurrent investigational drugs
- No concurrent dipyridamole or allopurinol
- No concurrent sorivudine or sorivudine analogs (e.g., brivudine) (capecitabine arm only)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- マスキング:なし(オープンラベル)
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
---|
1年生存
|
二次結果の測定
結果測定 |
---|
毒性
|
生活の質
|
客観的回答率
|
Median survival rate
|
Survival rate at 2 years
|
協力者と研究者
スポンサー
捜査官
- Emily Owen、Cancer Research UK
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
膵臓癌の臨床試験
-
Washington University School of MedicineUniversity of Oklahoma Medical Center; Northwestern University Chicago Illinois; Saint Luke's...完了
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); Highlight Therapeutics積極的、募集していない平滑筋肉腫 | 悪性末梢神経鞘腫瘍 | 滑膜肉腫 | 未分化多形肉腫 | 骨の未分化高悪性度多形肉腫 | 粘液線維肉腫 | II期の体幹および四肢の軟部肉腫 AJCC v8 | III期の体幹および四肢の軟部肉腫 AJCC v8 | IIIA 期の体幹および四肢の軟部肉腫 AJCC v8 | IIIB 期の体幹および四肢の軟部肉腫 AJCC v8 | 切除可能な軟部肉腫 | 多形性横紋筋肉腫 | 切除可能な脱分化型脂肪肉腫 | 切除可能な未分化多形肉腫 | 軟部組織線維肉腫 | 紡錘細胞肉腫 | ステージ I 後腹膜肉腫 AJCC (American Joint Committee on Cancer) v8 | 体幹および四肢の I 期軟部肉腫 AJCC v8 | ステージ... およびその他の条件アメリカ